World J Nephrol. Mar 25, 2026; 15(1): 113952 Published online Mar 25, 2026. doi: 10.5527/wjn.v15.i1.113952
Integrating Modified National Early Warning Score 2, computed tomography staging, and laboratory markers for enhanced prognostic stratification in emphysematous pyelonephritis
Cagri Sevik, Akif Erbin, Halil Lutfi Canat
Cagri Sevik, Akif Erbin, Halil Lutfi Canat, Department of Urology, Health Science University (Turkey), Basaksehir Çam and Sakura City Hospital, Istanbul 34300, Türkiye
Author contributions: Sevik C, Erbin A, and Canat HL contributed to study concept and design, data analysis, drafting of manuscript, and critical revision of the manuscript. All authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Akif Erbin, Associate Professor, Department of Urology, Health Science University (Turkey), Basaksehir Çam and Sakura City Hospital, G-434 Street, Istanbul 34300, Türkiye. akiferbin@hotmail.com
Received: September 9, 2025 Revised: October 20, 2025 Accepted: December 25, 2025 Published online: March 25, 2026 Processing time: 186 Days and 22.6 Hours
Core Tip
Core Tip: Emphysematous pyelonephritis is a rapidly progressive and life-threatening infection that necessitates timely and precise prognostic evaluation. Although the Modified National Early Warning Score 2 provides valuable risk information based exclusively on physiological parameters, clinical deterioration typically manifests at a relatively advanced stage. In contrast, computed tomography based staging and critical laboratory indicators, including anemia, thrombocytopenia, leukocytosis, and hyperglycemia, may yield earlier prognostic insights before overt vital-sign abnormalities develop. A combined assessment incorporating Modified National Early Warning Score 2, computed tomography classification, and laboratory indicators may therefore improve early risk stratification, inform timely nephrectomy decisions in high-risk patients, and ultimately optimize clinical outcomes.
